DURECT Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
DURECT Stock Forecast and Price Target
The average price target for DURECT's stock of $6.75 recently provided by two leading analysts would represent a 633.7% upside from its last closing price if reached. This potential increase is based on a high estimate of $8.50 and a low estimate of $5.00. Even if you are not interested in DRRX stock, it is still imperative to be aware of its competitors.
633.70% Upside
DURECT Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, DURECT's Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that DURECT's Fair Value will increase in the upcoming year, reaching $0.99. This would represent an increase of 100.00%. Over the next seven years, experts predict that DURECT's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.47 | Buy/Sell | $11.73 | 4.62% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.31 | Buy/Sell | $41.00 | 36.47% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF72.10 | Buy/Sell | CHF76.55 | 29.76% |
DURECT Revenue Forecast for 2023 - 2025 - 2030
In the last two years, DURECT's Revenue has decreased from $30.11M to $19.28M – a 35.97% drop! The next year, 4 experts forecast that DURECT's Revenue will decrease by 8.87%, reaching $17.57M. Over the next seven years, experts predict that DURECT's Revenue will grow at a rate of 3684.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$35.84 | Buy/Sell | $37.75 | 11.61% |
| ZVRA Stock Forecast | Zevra Therapeutics | Buy |
10
|
$4.52 | Buy/Sell | $19.50 | 309.29% |
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.03 | Buy/Sell | $8.50 | -100.00% |
.jpg)
DURECT EBITDA Forecast for 2023 - 2025 - 2030
DURECT's EBITDA has grown in the last two years, jumping from $-12.32M to $-34.96M – an increase of 183.77%. According to 0 prominent analysts, DURECT's EBITDA will fall by 23.10% in the next year, reaching $-26.89M. By 2030, professionals believe that DURECT's EBITDA will decrease by 20.08%, reaching $-27.94M – a concerning trend for the company.
DURECT EBIT Forecast for 2023 - 2025 - 2030
In the last two years, DURECT's EBIT has increased by 177.97%, going from $-12.62M to $-35.08M. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $-52.91M – an increase of 50.83%. In 2030, professionals predict that DURECT's EBIT will decrease by 1045.55%, to $331.70M.
DURECT EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, DURECT's EPS has seen an increase, rising from $-0.70 to $0.00. This represents a growth of 100.00%. Analysts predict that DURECT's EPS will increase in the upcoming year, reaching $-1.70. This would represent an increase of 100.00%. Over the next seven years, experts predict that DURECT's EPS will grow at a rate of 100.00%.
.jpg)